At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 318 enrolled
Drug / intervention
cyclophosphamide +10 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 2 clinical trial evaluating cyclophosphamide, cytarabine, and 9 other interventions for Leukemia. Completed, enrolled 318 participants.
Detailed Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
Countries--
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartMar 2008
Primary CompletionSep 2016
Study CompletionJun 2024
TodayJul 2026
First PostedNov 15, 2007
Enrollment StartMar 12, 2008
Primary CompletionSep 1, 2016
Study CompletionJun 24, 2024
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 18.6 years ago
Interventions
cyclophosphamidedrug
cytarabinedrug
daunorubicin hydrochloridedrug
dexamethasonedrug
doxorubicin hydrochloridedrug
mercaptopurinedrug
methotrexatedrug
pegaspargasedrug
thioguaninedrug
vincristine sulfatedrug
radiation therapyradiation